Dataset Open Access

Determining the IC50 values of 30 legacy ACVR1/ALK2 inhibitors

Wong, Jong Fu; Bullock, Alex

A large number of ACVR1/ALK2 inhibitors were previously synthesised by Paul Brenner’s team (Target Discovery Center, University of Oxford) for the purpose of treating Fibrodysplasia Ossificans Progressiva (FOP). Although these compounds were not designed with blood-brain-barrier permeability in mind, they can serve as good bench-marks for my cellular assays. Therefore, 30 of these legacy compounds were chosen to be tested before other new bespoke Diffused Intrinsic Pontine Glioma (DIPG) compounds from Ontario Institute for Cancer Research (OICR) and Charles River Laboratories (CRL).

Files (335.5 kB)
Name Size
Zenodo post009.pdf
335.5 kB Download
All versions This version
Views 157114
Downloads 7940
Data volume 26.5 MB13.4 MB
Unique views 12298
Unique downloads 6838


Cite as